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ABSTRACT 25 
The persistence of latently HIV-infected cells in patients under combined anti-26 
retroviral treatment (cART) remains the major hurdle for HIV eradication. Thus far, 27 
individual compounds have not been sufficiently potent to reactivate latent virus and 28 
guarantee its elimination in vivo. Thus, we hypothesized that transcriptional 29 
enhancers, in concert with compounds triggering the innate immune system, are 30 
more efficient in reversing latency by creating a Th1 supportive milieu that acts 31 
against latently HIV-infected cells at various levels. To test our hypothesis, we 32 
screened six compounds on a co-culture of latently infected cells (J-lat) and 33 
monocyte-derived dendritic cells (MDDCs). The PKC agonist, Prostratin, with a TLR8 34 
agonist, resulted in greater reversion of HIV latency than any single compound. This 35 
combinatorial approach led to a drastic phenotypic and functional maturation of the 36 
MDDCs. TNF and cell-cell interactions were crucial for the greater reversion 37 
observed. Similarly, we found a greater potency of the combination of 38 
Prostratin/TLR8 agonist in reversing HIV latency when applying it to primary cells of 39 
HIV-infected patients. Thus, we demonstrated here the synergistic interplay between 40 
TLR8-matured MDDCs and compounds acting directly on latently HIV-infected cells, 41 
targeting different mechanisms of latency, by triggering various signaling pathways. 42 
Moreover, TLR8 triggering may reverse exhaustion of HIV-specific cytotoxic T 43 
lymphocytes that might be essential for killing or constraining the latently infected 44 
cells.   45 
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IMPORTANCE 46 
Curing HIV is the Holy Grail. The so-called “shock and kill strategy” relies on drug-47 
mediated reversion of HIV latency and the subsequent death of those cells under 48 
combined anti-retroviral treatment. So far, no compound achieves efficient reversal of 49 
latency nor eliminates this latent reservoir. The compounds may not target all of the 50 
latency mechanisms in all latently infected cells. Moreover, HIV-associated 51 
exhaustion of the immune system hinders the efficient elimination of the reactivated 52 
cells. In this study, we demonstrated synergistic latency reversion by combining 53 
agonists for protein kinase C and toll-like receptor 8 in a co-culture of latently infected 54 
cells with myeloid dendritic cells. The drug Prostratin stimulates directly the 55 
transcriptional machinery of latently infected cells and the TLR8 agonist acts 56 
indirectly by maturing dendritic cells. These findings highlight the importance of the 57 
immune system and its activation, in combination with direct acting compounds, to 58 
reverse latency.   59 
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INTRODUCTION 60 
The HIV-1 pandemic remains a major global health threat. While combined anti-61 
retroviral treatment (cART) effectively suppresses HIV replication, the virus rebounds 62 
when treatment is interrupted (1-5), pointing to a reservoir of latently infected cells. 63 
Indeed, a replication-competent but silent reservoir in long-lived latently HIV-infected 64 
cells is established early after HIV transmission and is not targeted by cART (6-8).  65 
The latently infected cells are primarily resting memory CD4+ T cells. Latency is 66 
maintained by restricting access of the transcriptional machinery to the proviral DNA 67 
(9-13), and epigenetic regulation further constrains the positive Tat feedback loop 68 
(14). Moreover, key transcription factors, such as NFκB (15-17) and NFAT, as well as 69 
the transcription elongation factor PTEFb (18-22), are tightly sequestered in the 70 
resting state.  71 
Latency may be reversed by releasing transcriptional or epigenetic blocks, 72 
decreasing the cell activation threshold (PD-1, LAG-3), or enhancing the 73 
transcriptional noise (23). The “shock and kill” strategy takes advantage of these (24-74 
26). Reactivation of HIV production induces direct or indirect cell death that is 75 
mediated by HIV-specific cytotoxic T lymphocytes (CTL), natural killer (NK) cells (27), 76 
or antibody-dependent cellular cytotoxicity (ADCC) under cART (28, 29). This 77 
strategy should result in a sterilizing cure. However, clinical trials (e.g., using IL-2 (30-78 
33) alone or in concert with IFN-γ (34), IL-7 (35-37) or the CD3 antibody OKT-3) have 79 
been disappointing: all the patients relapsed upon cART interruption. Moreover, in 80 
the case of OKT-3 (38), CD4+ T cell levels dropped dramatically or even an 81 
expansion of the proviral reservoir was observed for IL-7 (36).  82 
Recent oncological clinical trials (39-41) have encouraged the in vivo use of 83 
protein kinase C agonists (PKCag) in humans. PKCag (i.e., Prostratin, a non-84 
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tumorigenic phorbol ester (42-46), Bryostatin (47, 48) and Ingenol (49, 50)) are 85 
potent HIV transcription inducers that release NFkB, AP1 and PTEFb (51, 52). 86 
However, their applications have been limited by their toxicity and difficulty of 87 
synthesis. Nonetheless, their promising profile, combined with the generation of 88 
potent analogs, might support their clinical development as latency reversing agents 89 
(LRAs) in vivo (53). 90 
Based on the importance of epigenetics for HIV transcription, inhibitors of histone 91 
deacetylase (HDACi) are believed to be promising LRAs (54-57). One of these, 92 
Vorinostat, was safe and efficacious in promoting transcription of cell-associated HIV 93 
RNA in CD4+ T cells, but no decrease in the number of infected cells was achieved. 94 
Another pan-HDACi, Panobinostat, induced HIV transcription more efficiently than 95 
Vorinostat. Intriguingly, the transient decline of total HIV DNA correlated with 96 
stimulation of the innate immune system, mainly activation of NK and plasmacytoid 97 
dendritic cells (pDC) (56). Thus, support from the immune system seems to be 98 
needed to clear the latently infected cells, as reversion from HIV latency alone is 99 
insufficient to induce cell death (58), most likely because of low viral production (59). 100 
Moreover, impaired HIV-specific CTL responses (60, 61), CTL escape HIV variants 101 
(62) in concert with the immaturity of DCs (63-65), emphasize the need of re-102 
enforcing the immune system, in particular, the HIV-specific CTLs, to deplete the 103 
infected cells  104 
Various promising strategies target the innate immune system that will eliminate 105 
cells switching from latent to productive HIV infection. Among the most promising are 106 
toll-like receptors (TLRs), such as TLR9 (66), TLR8 (67), and TLR1/2 (68). TLR7 on 107 
DCs (69), in particular, has emerged as an approach to induce HIV transcription and 108 
direct a cytotoxic immune response. Indeed, TLR triggering modulated DC activity, T 109 
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helper and macrophage polarization (70-72) and displayed various effects on HIV 110 
replication (73, 74). Notably, TLR7, 8 and 9 are expressed on DCs, and their 111 
stimulation resulted in DC-dependent changes of the microenvironment. TLR 112 
signaling could also act on the apoptosis sensitivity of immune and cancer cells (75). 113 
Altogether, TLR triggering is a promising multifactorial adjuvant to eliminate the latent 114 
reservoir. It induces HIV expression and antiviral cytokine production, which 115 
interferes with spreading infection as well as T- and NK-cell maturation, which might 116 
deplete HIV-infected cells. 117 
Here we proposed that concomitant use of transcriptional enhancers and immune 118 
response inducers is a potent strategy for reactivating HIV replication. Acting on 119 
different transcriptional repression mechanisms is most likely key factor for efficient 120 
reversion of HIV latency (76, 77). We tested the hypothesis that Prostratin (acting 121 
directly on latently infected T-cells), in concert with TLR8ag (acting via DC), disrupts 122 
HIV latency (67) and might trigger the priming and restoration of antigen-specific 123 
immunity, through co-stimulatory molecules and IL-12p70 expression (72, 78, 79). 124 
Adding TLR8ag might lead to a Th1 supportive milieu crucial to clear the persistent 125 
quiescent reservoir in vivo. To explore this possible interplay, J-lat cells were co-126 
cultured with monocytes-derived dendritic cells (MDDCs), representing the 127 
inflammatory DC compartment (80-82), and subsequently challenged with diverse 128 
compounds. The reactivation potency was evaluated using LTR-driven eGFP 129 
expression and the overall outcome by characterizing both players. In a second step, 130 
we verified this approach on primary cells from aviremic patients.   131 
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MATERIALS AND METHODS 132 
Antibodies and reagents.  133 
Prostratin (P0077), 5-aza-2'deoxycytidine (Aza-CdR, A3656), Azidothymidine (AZT, 134 
A2169) and Efavirenz (SML0536) were purchased from Sigma-Aldrich. Prostratin and 135 
Aza-CdR were used at 0.5 μM, AZT was used at 5 μM and Efavirenz at 50 nM.  Rh-136 
GM-CSF, rh-IL-4 and TNF (10 ng/ml) were obtained from Immunotools (#11343127, 137 
#11340017 and #113440047, respectively). TLR8ag (3M-002), used at 1 μM, was 138 
purchased from 3M-Pharmaceuticals (St. Paul, MN; 55144-1000). Finally, SAHA, 139 
obtained from Cayman (#10009929), was used at 1 μM unless otherwise stated in 140 
the figure legends. Blocking antibodies CD80 and CD86 (Biolegend, #305201, 141 
305401) were applied at 5 μg/ml and Infliximab was from R&D Systems (AF-210-NA) 142 
and used at 1 μg/ml for the TNF blocking experiments. The ImmunoCultTM Human 143 
CD3/CD28/CD2 T cell activator (#10970) from Stemcell Technologies was used 144 
based on the manufacturer’s instructions. Flow cytometry antibodies were purchased 145 
either from Pharmingen (i.e., active Caspase3-PE (#550821), CD80-PE (#557227), 146 
CD83-PE (#556855), CD86-PE (#555658), or Biolegend, as CTLA-4-APC (#349907), 147 
ICOS-PE/Cy7 (#313519), DC-SIGN-FITC (#330103), HLA-DR-APC (#307609), or 148 
from Beckman Coulter p24-RD1 (#6604667). Finally, acetylated lysine-9 of histone 149 
H3 (H3K9-ac) antibody was obtained from Abcam (Cambridge, UK, #10812). The 150 
signaling inhibitors library, kindly provided by Prof. B. Schaefer and mainly originating 151 
from AxonMedchem, Selleck and Sigma-Aldrich, was applied for 1 h, at a final 152 
concentration of 500 nM, on J-lat cells alone before adding the MDDCs in 153 
combination with the stimuli.  154 
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Cell culture.  155 
J-lat, J1.1, ACH2 and 8E5 cells, obtained from NIH (#9848, #1340, #349 and #95, 156 
respectively), were cultured in R-10 medium (i.e., RPMI 1640 medium (BioWhittaker) 157 
supplemented with 10% FCS, 2 mM L-glutamine and 1% penicillin/streptomycin 158 
(Gibco). J-lat and J1.1 cells were both derived from Jurkat cells (83, 84). MDDCs 159 
were generated by 7 days of stimulation of monocytes, isolated from healthy donors 160 
with CD14 microbeads (Miltenyi, #130-050-201), with 1’000 biologically active units 161 
per ml of rh-IL-4 and rh-GM-CSF. J-lat or J1.1 cells (105) were seeded in a 96-well 162 
plate with or without 104 MDDCs and cultured/treated for 24 h. J-lat cells and MDDCs 163 
were separated in a 24-well plate by applying a transwell (Millipore, Millicell, 164 
PIHP01250) with a pore size of 0.4 μm. Blocking antibodies CD80 and CD86 were 165 
pre-incubated 1 h before adding J-lat and the treatments. Azide (0.09 %), included in 166 
the CD80 and 86 blocking antibodies was added to the mock control. 167 
Patients 168 
We had access to specimens from HIV-infected patients successfully treated by 169 
cART (<20 copies/ml, as measured by the Cobas® Amplicor technology, Roche) for 170 
more than 4 years (median 12.5 years) with a median of 584 CD4+T cells/μl. The use 171 
of these specimens was approved by the Ethics Committee of the University Hospital 172 
Zurich and informed consent was obtained from all HIV-1-infected individuals 173 
recruited. All experiments were performed in accordance with the relevant guidelines 174 
and regulations. 175 
PBMC were isolated from 30 ml of blood by Ficoll (Axis-Shield PoC AS, Norway) 176 
gradient centrifugation, followed by CD8+ T-cell -depletion using microbeads 177 
(Miltenyi, #130-045-201), and CD14+ cell isolation as previously described. The 178 
 o
n
 January 26, 2017 by UZH Hauptbibliothek / Zentralbibliothek Zuerich
http://jvi.asm.org/
D
ow
nloaded from
 
9 
 
remaining PBMC were cryopreserved until MDDCs’ differentiation, and CD4+ T cells 179 
were then indirectly isolated (Miltenyi, # 130-096-533). Limited blood volume and cell 180 
numbers restrained the experiment setup to 105 CD4+ T cells and 104 MDDCs per 181 
well in quintuplicate. These autologous co-cultures were stimulated with either 182 
Prostratin, TLR8ag, both combined, or anti-CD3/CD28/CD2 antibodies. AZT and 183 
Efavirenz were added to all the conditions. At day 2, 5, 7 and 9, 50 μl of supernatant 184 
per well was collected, pooled per donor and treatment, and was analyzed for HIV 185 
RNA copy numbers. Medium was replaced twice a week until the end of the 186 
experiment.  187 
Flow cytometry.  188 
J-lat clone 9.2, MDDCs or both combined were incubated with the cell-surface 189 
marker antibody at an optimized dilution in FACS buffer (PBS containing 2 mM 190 
EDTA, 0.1 % sodium azide and 10 % FCS) for 20 minutes at 4 °C. Cells were 191 
subsequently washed with FACS buffer and fixed with 1 % paraformaldehyde (PFA) 192 
in PBS until acquisition. Permeabilization kit (BD, cytofix/cytoperm, #554714) was 193 
used for intracellular staining for active Caspase-3, H3K9-ac and p24 antigen 194 
according to the manufacturer’s instructions. Stained cells were acquired on a CyAn 195 
TM ADP Analyzer (Beckman Coulter), and data were analyzed using FlowJo (version 196 
V.10.0.8). We defined the live cells by the side scatter/forward scatter gate and then 197 
quantified the number of cells by the specific marker of interest. 198 
Cytokine measurements.  199 
Supernatants (SN) of stimulated MDDCs were collected at 6, 12, 24 and 36 h and 200 
subjected to quantification of TNF, MIP1α and IL12-p70. Human cytokines were 201 
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analyzed using a multiplexed particle-based flow cytometric cytokine assay (85). 202 
Cytokine kits were purchased from R&D Systems. The procedures closely followed 203 
the manufacturer’s instructions. The analysis used a conventional flow cytometer 204 
(Guava EasyCyte Plus, Millipore, Zug, Switzerland). The values (pg/ml) obtained 205 
were normalized on the mock-treated control. 206 
Viral RNA measurements. 207 
HIV RNA was isolated from 250 µl culture supernatant using the QIAmp Viral RNA 208 
Mini Kit (Qiagen, #52906). Serial dilution of PBMC-propagated Yu2, quantified by 209 
Cobas® Amplicor technology (Roche), were simultaneously isolated and used as 210 
standards. Subsequently, viral RNA was reverse transcribed using the iScriptTM 211 
Select cDNA Synthesis Kit (Bio-Rad, #170-8897) in combination with a gene-specific 212 
primer (0.25 μM reverse, TACTAGTAGTTCCTGCTATGTCACTTCC). HIV DNA was 213 
amplified using the Maxima Hot Start PCR Master Mix (Thermo Scientific, K1052), 214 
with 1 μM forward primer (5’-CAAGCAGCCATGCAAATGTTAAAAGA-3’), 0.3 μM 215 
probe (5’-FAM-TGCAGCTTCCTCATTGATGGT-BHQ1-3’) and 1 μM of the above 216 
mentioned reverse primer. Cycling conditions were 95 °C for 4 min, and then 50 217 
cycles of 95 °C for 5 sec, 55 °C for 5 sec and 60 °C for 30 sec. Reactions were 218 
performed on a Bio-Rad iCycler (170-8740) and analyzed with the IQ5 software 219 
(Biorad). Copy numbers (copies/ml) were adjusted to the initial volume of 220 
supernatant.  221 
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Statistics  222 
The software GraphPad Prism Version 5.04 was used for doing statistics. The 223 
statistical test employed is indicated in the legends. Two-tailed paired t-test was 224 
performed on the individual replicates between parameters, otherwise stated. Mann-225 
Whitney test and ANOVA were used for the viral RNA peak value statistics. P≤0.5 226 
was considered statistically significant.  227 
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RESULTS 228 
Differential potency of LRA on J-lat clones alone or co-cultured with MDDCs  229 
We first screened various J-lat clones (83) for their signal-to-noise ratios by looking at 230 
their LTR-driven eGFP expression when stimulated with Prostratin, Aza-CdR, or TNF 231 
± Aza-CdR (Fig. 1A)). Several clones (i.e., clone 6.3, 8.4, 9.2 and 15.4) had good 232 
signal-to-noise ratios, and we eventually used clone 9.2 for all experiments. 233 
We believe that the immune system and in particular myeloid dendritic cells 234 
(mDCs) are key players in HIV cure. They generate a microenvironment potentiating 235 
the effects of LRAs and enabling an HIV-specific CTL response. Thus, we designed a 236 
co-culture of latently infected T cells, represented by the J-lat clone 9.2 and MDDCs 237 
at a ratio 10:1. Without any exogenous stimuli, this set-up did not alter the 238 
reactivation latency background of J-lat 9.2 but tended to increase ICOS and CTLA-4 239 
expression, pointing  to a potential activation of J-Lat cells by the MDDCs (86, 87) 240 
(data not shown).  241 
Then, we challenged several known LRAs, including PKCag, HDACi, and DNA 242 
methyltransferase inhibitor, and various TLR agonists (TLRag) for their ability to 243 
reverse latency in J-lat cells alone (Fig. 1B, upper panel) or co-cultured with MDDCs 244 
(Fig. 1B, lower panel). In J-lat monoculture, HIV was effectively induced by SAHA 245 
and TNF, as reported (88). Prostratin, Trichostatin A (TSA), Aza-CdR as well as 246 
TLR2, 4, and 8ag had modest or no effect. The lack of reversion in J-lat cells by 247 
TLRs is consistent with their low or absent levels of TLR2, 4 and 8 mRNA 248 
expression, which was not altered upon stimulation (data not shown). Strikingly, 249 
Prostratin in co-culture led to greater HIV reactivation than any other compound (Fig. 250 
1B). These data underlined the importance of studying potential LRAs and their 251 
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combinations in a more complex system than pure T-cell cultures. Moreover, it 252 
prompted us to focus primarily on Prostratin as an adjunct to immune inducers that 253 
act via other immune cells, such as mDCs. Triggering TLR4 and 8 in co-culture also 254 
induced HIV transcription to a similar level as SAHA. 255 
Prostratin achieved superior HIV latency reversion in co-culture, further 256 
enhanced by TLR8 agonist.  257 
Prostratin showed a dose-dependent reversion of latency in J-lat 9.2 cells with 258 
moderate effects at 1 µM and minimal ones at 0.1 µM (Fig. 2A). Notably, the extent of 259 
reversion correlated with cell death rate (Fig. 2B), which is most likely mediated by 260 
viral cytopathicity and not due to drug-induced toxicity. The latter explanation is 261 
supported by the higher viability of the parental Jurkat cells when exposed to similar 262 
concentration of Prostratin, i.e., 71 % compared to 49 % in J-lat 9.2 (Fig. 2C).  263 
Adding the immune inducer TLR8ag to Prostratin in the co-culture system resulted in 264 
much greater reversion of latency than the PKCag alone (Fig. 2D). This effect was 265 
also seen with other TLR agonists, such as TLR2 and TLR4 agonists (data not 266 
shown). Indeed, adding TLR8ag sensitized J-lat cells to lower concentrations of 267 
Prostratin without any additional toxicity (Fig. 2E). Furthermore, this combination 268 
resulted in higher eGFP mean fluorescence intensity (MFI), which suggests stronger 269 
HIV transcription and thus viral particle production (Fig. 2F). Additionally, we 270 
observed a plateau of efficacy at 0.5 μM of Prostratin, supporting this concentration 271 
for the subsequent use.  272 
Effects of Prostratin and/or TLR8ag on other latently HIV-infected cell lines. 273 
We wanted to corroborate the data obtained in other T-cell lines. We screened the 274 
latently infected T-cell lines, 8E5, ACH2 and J1.1. 8E5 cells produced continuously 275 
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HIV particles as measured by staining for intracellular p24 (data not shown). ACH2 276 
cells showed close to 100% reversion of latency in response to Prostratin and TNF at 277 
the doses used for the J-lat cells 9.2 (data not shown). Thus, we did not pursue any 278 
additional experiments with these two cell lines.  279 
The J1.1 cell monoculture reached a reversion of latency of 61.5 % ± 1.99 with TNF 280 
and 30.95 % ± 0.49 with Prostratin (Fig. 3). In the co-culture setup, the J1.1. cells 281 
were more responsive to Prostratin with 42.37 % ± 6.28 cells positive for intracellular 282 
p24 antigen (Ag) than in the monoculture. However, Prostratin in concert with 283 
TLR8ag resulted in a similar frequency of reverted cells as with TNF alone. Adding 284 
the TNF blocker Infliximab to the co-culture treated with Prostratin/TLR8ag 285 
recapitulated the findings found in J-lat cells; the remaining latency reversion was 286 
greater, although not significantly, than the one observed in co-cultures treated with 287 
Prostratin and Infliximab pointing to the causal role of other soluble factors or cell-cell 288 
contact herein. The effects observed with J1.1 were less prominent compared to J-lat 289 
9.2 cells, at the doses established in the latter one.     290 
TNF and cell-cell interaction are involved in the enhanced reactivation in co-291 
culture.  292 
Using transwells and Infliximab, we explored the mechanisms that led to the 293 
increased reversion of latency (Fig. 4A). Indeed, separation of the two cell types, as 294 
well as inhibiting TNF signaling drastically reduced the synergy of Prostratin and 295 
TLR8ag up to 70 %. A combination of transwells and Infliximab abrogated this 296 
positive interplay up to 95 %. The remaining latency reversing activity corresponded 297 
to the modest effect of Prostratin on J-lat cells. These findings underlined the major 298 
role of soluble factors and cell-cell contact for the reversion of latency in our model.  299 
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We verified that the dose of Infliximab added to the co-culture was sufficient to 300 
neutralize all TNF produced by MDDCs. We added increasing amount of TNF to the 301 
J-lat cells while keeping the dose of infliximab constant. 1 μg/ml of Infliximab inhibited 302 
the reversion of latency in J-Lat cells treated with 100 ng/ml of TNF (Fig. 4B), which 303 
is 5 fold more than the maximum of TNF released by TLR8ag stimulated MDDCs 304 
over 24 h (5-20 ng/ml, data not shown). This experiment substantiates the conclusion 305 
that TLR8ag stimulated MDDCs act also by other means, as cell-cell contact, than 306 
TNF on J-lat cells for reverting latency. 307 
 Short exposure of MDDCs to solely TLR8ag was sufficient to mediate potent eGFP 308 
expression in J-lat cells consistent with their rapid and efficient maturation (Fig. 4C). 309 
The signal was slightly lower than the control and implied a direct role of Prostratin in 310 
the activation/maturation of MDDCs. Conversely, MDDCs cultured for 1 h with 311 
Prostratin, followed by washing and adding J-lat cells with TLR8ag, resulted in a 312 
reduced response, pointing to the absolute need of Prostratin for J-lat reactivation 313 
(Fig. 4C). Finally, we explored whether supernatants from MDDCs would have any 314 
effect on latency reversion in J-lat cells. The cells were pre-treated for 2 h to achieve 315 
maximal stimulation, washed and further cultured without stimuli for 24 h. When the 316 
supernatant was transferred onto J-lat cells, we only observed background eGFP 317 
expression, explained by the unstable nature of the factors secreted by the MDDCs 318 
(Fig. 4C). Furthermore, Prostratin and TNF stimulation of J-lat cells or supernatant 319 
transfer of TLR8ag-treated MDDCs supplemented with Prostratin, led to a lower 320 
reversion of latency than Prostratin and TLR8ag added directly to co-cultures (Fig. 321 
4D).  322 
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Altogether, these findings demonstrated the role of Prostratin, TNF and cell-cell 323 
interaction in the enhanced latency reversion in co-culture.  324 
Thus, multiple pathways must be stimulated for a sustained induction of NF-κB and 325 
de novo synthesis of Tat, which is required for robust expression of elongated HIV 326 
transcripts (89). Prostratin appears to be essential to initiate HIV transcription on J-lat 327 
cells, which is further enhanced by the concomitant stimulation by TLR8-matured 328 
MDDCs via TNF and co-stimulatory molecules.  329 
Prostratin and TLR8ag modulated the phenotypic and functional 330 
characteristics of MDDCs but CD80-86 and ICOSL had no role in the enhanced 331 
reversion of latency in co-cultures exposed to TLR8ag and Prostratin.  332 
We considered the phenotypic and functional changes of MDDCs essential for 333 
understanding the superior latency reversion in response to TLR8ag and Prostratin, 334 
and especially for further development of this approach. Prostratin led to an 335 
adherent, constellation-like phenotype of MDDCs (data not shown) and induced 336 
minor CD80 and CD83 expression at 24 h. In contrast, the percentage and MFI of 337 
CD86 were substantially increased within 12 h and remained elevated over the entire 338 
observation period of 36 h (Fig. 5A upper panel; data not shown). Further, Prostratin 339 
promoted TNF production as reported (45) and a transient MIP1α secretion at 12 h 340 
but without any induction of IL-12p70 (Fig. 5B). We also observed increased HLA-DR 341 
expression concomitant with DC-SIGN downregulation (Fig. 5C). Therefore, 342 
Prostratin might restrain spreading infection through DC-SIGN reduction and 343 
enhancing antigen presentation by upregulating HLA-DR. These findings highlighted 344 
the pleiotropic effects of Prostratin in MDDCs that might contribute to a less 345 
permissive micro-environment for HIV dissemination.  346 
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As expected, TLR8ag triggered rapid upregulation of maturation markers (Fig. 5A, 347 
lower panel) and sustained production of TNF (Fig. 5B). Importantly, with the 348 
increasing secretion of IL-12p70, TLR8 stimulation might license mDCs to rescue the 349 
adaptive immune response from HIV-associated exhaustion. In addition, Prostratin 350 
and TLR8ag did not antagonize each other (Fig. 5C). 351 
Thus, Prostratin and TLR8ag induced a functional maturation of MDDCs, optimal for 352 
the reversion of latency. Furthermore, the recruitment of immune cells by MIP-1α, the 353 
reduced capture and transmission of HIV virions by mDC, in combination with IL-354 
12p70 secretion and enhanced MHCII antigen-presentation, might promote a Th1 355 
response  356 
that contributes to an HIV-restrictive environment.  357 
Next, we tried to identify the receptor-ligand pair involved in the cell-mediated 358 
enhanced reversion of latency. We focused primarily on the CD80/86-CD28 axis 359 
since these costimulatory molecules were substantially increased on MDDCs treated 360 
with Prostratin and TLR8ag (Fig. 5A). Strikingly, suppressing the CD80/86 axis with 361 
neutralizing antibodies (NAb) further increased reversion of latency in this setting 362 
(Fig. 5D). We explain this result by a preferential interaction of CD80/86 with the 363 
inhibitory receptor CTLA-4 (Fig. 5E). Therefore, its blocking potentially removed 364 
some inhibitory pressure on the signaling pathways triggered by Prostratin and 365 
TLR8ag.  366 
The CD28 family member, ICOS, was also significantly up-regulated in Prostratin 367 
treated co-culture (Fig. 5.E), irrespective of TLR8ag. However, blocking ICOSL with 368 
up to 10 ug/ml of NAb did not reduce eGFP expression, excluding ICOSL as relevant 369 
costimulatory molecule for latency reversion (data not shown).  370 
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Prostratin triggered moderate apoptosis in J-lat cells and had no deleterious 371 
effect on MDDCs.  372 
LRAs may induce cell death in the target cells by reversion of latency but also in 373 
uninfected cells. Prostratin alone induced moderate apoptosis in J-lat cells, as 374 
quantified by active Caspase-3 (Fig. 6A). Prostratin or TLR8ag displayed no toxicity 375 
on MDDCs (Fig. 6B). Similarly, the combined treatment of Prostratin and TLR8ag on 376 
co-culture did not show any additive or synergistic detrimental effects on J-lat cells 377 
(Fig. 6C). Importantly, apoptosis induction was positively correlated with eGFP 378 
expression in J-lat cells (Fig. 6D), but was lost in the co-culture setup (Fig. 6E).   379 
Consistent with its anti-tumor activity, SAHA triggered a high level of apoptosis in J-380 
lat cells, in MDDCs as well as in co-cultures (Fig 6A, B, C). SAHA’s apoptosis rate 381 
was even higher than its effect on reversion of latency, especially in co-culture (Fig. 382 
6D, E) highlighting its potential cellular toxicity. 383 
Prostratin and TLR8ag stimulated co-cultures increased moderately but 384 
significantly the chromatin accessibility, enabling HIV transcription.  385 
Since relaxation of the chromatin is crucial for transcription factors access and for 386 
initiation of efficient HIV transcription, we examined the global chromatin relaxation in 387 
response to our treatments, by measuring the histone H3 lysine 9 acetylation (H3K9-388 
ac).  Prostratin with and without TLR8ag showed no effect on chromatin relaxation. in 389 
J-lat cells alone (Fig. 7). In contrast, co-cultures stimulated with both compounds led 390 
to a significant chromatin relaxation compared to the mock treated co-culture.  The 391 
effect on chromatin relaxation overall was not very prominent, but a given signaling 392 
pathway, e.g., TLR8, most likely alters sparse regions of the chromatin (90). 393 
Furthermore, the one shot analysis done at 24 hours will not mirror the dynamic 394 
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changes over time (91). Therefore, the minor changes observed on the overall 395 
chromatin remodeling may be well sufficient for enhanced HIV transcription in the 396 
context of combined treatment with Prostratin and TLR8ag. In contrast, SAHA 397 
drastically modified the acetylation status of H3K9 (up to 70 %), which was not 398 
correlate with the reversion of HIV latency. 399 
SYK, MEK, PKCβ mediated the enhanced reversion of latency by Prostratin and 400 
TLR8ag in co-culture. 401 
To assess the signaling pathways involved, we used a library of inhibitors (kindly 402 
provided by Prof. Schäfer). In Prostratin/TLR8ag treated co-culture, inhibition of SYK, 403 
MEK (1-2) and PKCβ resulted in the most striking loss of latency reversion (Fig. 8A). 404 
This finding is consistent with the central role of SYK in the immune-receptor pathway 405 
in hematopoietic cells. Furthermore, activation of the PKC pathway via Prostratin, 406 
was demonstrated by the reduced eGFP expression upon PKCβ inhibition. As SYK 407 
and PKC signal through MEK/ERK/NFκB, blocking MEK interferes with both 408 
pathways. 409 
In co-culture treated with Prostratin, SYK, PKCβ and MEK were also involved (Fig. 410 
8B, red bars), as well as PDK1±TBK1 and GSK3. The PI3kinase activation appeared 411 
not to have any effect on reversion of latency in this setup (Fig. 8B, blue bar). 412 
Notably, the serine/threonine kinase TBK1 and GSK3 induce TLR-dependent NFκB 413 
nuclear translocation and TNF synthesis (92), pointing to the prominent contribution 414 
of NFκB. Inhibition of PKCβ and PDK1 in co-culture, only modestly reduced reversion 415 
of latency upon Prostratin and TLR8ag treatment,  as compared to Prostratin alone 416 
(Fig. 8B, C). We speculated that there were extensive cross-signaling events, 417 
creating some redundancy and thus lessening the role of PKCβ and PDK1 in the 418 
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overall response. We could neither detect any involvement of AKT, a downstream 419 
substrate of PDK1, nor JNK and p38, involved in TLR and TNF signaling (Fig. 8B, C). 420 
This phenomenon might be explained by a SYK-dependent inhibition of JNK and p38 421 
phosphorylation (93). Interestingly, inhibiting phospholipase C (PLC) led to an 422 
enhanced HIV transcription, especially in Prostratin-treated J-lat monoculture (Fig. 423 
8B, C).  424 
Latency reversion in co-cultures with cells from aviremic HIV-infected 425 
individuals in response to either Prostratin ± TLR8ag or CD3/CD28/CD2 426 
stimulation. 427 
Eventually, we examined our strategy using primary cells from HIV-infected 428 
individuals with suppressed HIV RNA (Table 1). We performed a co-culture of 429 
autologous CD4+ T cells and MDDCs. By adding the RT-inhibitors we detected 430 
exclusively the virions emerging from the latent reservoir and thereby we were able to 431 
estimate the potency of the various compounds.  432 
The limited number of specimens assessed and the rather large donor- and time 433 
dependent variability of the assay results prompted us to compare the average of 434 
mock-treated samples (p=0.23 between the donors, ANOVA) with all treated samples 435 
irrespective of the compound and time point. We observed a significant increase in 436 
viral RNA production upon simulation as compared to the mock condition (p=0.0052) 437 
(Fig. 9A). In most cases the increase was most prominent at day 5 after stimulation. 438 
Notably, we observed donor-dependent sensitivity to distinct LRAs, which is a well-439 
known phenomenon (94) (Fig. 9B). Even the specimens treated with anti-440 
CD3/CD28/CD2 (positive control) did not result in uniform latency reversion (i.e., 441 
donor 4 and 8). We also observed distinct magnitudes in latency reversion with the 442 
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various LRAs, e.g., in donor 6 and 9, Prostratin+TLR8ag was more potent than either 443 
compounds alone. At contrary, in donor 4 and 7, Prostratin+TLR8ag had not effect.   444 
We explain this heterogeneous result by donor-specific responsiveness to LRAs, 445 
reservoir size and underlying latency mechanisms.  446 
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DISCUSSION 447 
Here, we investigated the efficacy of compounds directly targeting latently infected T 448 
cells in concert with innate immune system stimulation. We found superior reversion 449 
of latency in a co-culture of T cells and MDDCs, in vitro and ex vivo, using cells from 450 
aviremic HIV-infected individuals, when exposed to the PKC agonist, Prostratin, and 451 
a TLR8 agonist. Soluble factors, in particular TNF, and cell-cell contact contributed to 452 
the superior reversion of latency. Notably, the TLR8-mediated IL12p70 increased 453 
secretion might be crucial for restoring antigen-specific CTL activity (95, 96). 454 
Therefore, such a combined approach might be very promising in latency reversion 455 
and conceivably in restoring adaptive immune responses needed to eliminate latently 456 
infected T-cells.  457 
The study of latently infected cells is challenging. Their frequency is quite low, 458 
contain a fraction of replication-competent but hardly inducible proviruses (i.e., 1/105–459 
106 T cells) (1, 97), and they cannot be segregated from their uninfected counterpart. 460 
Moreover, patients’ diversity, latently infected cells features as well as limited blood 461 
or tissues sampling impede screening of LRAs. Therefore, latency T cells models 462 
remain useful for challenging new “shock and kill” strategies. Various latency T-cell 463 
models have been generated (88), but they lack the influence of neighboring cells, 464 
such as DCs, in the nature and nurture of latently infected cells. We established a co-465 
culture model consisting of the HIV latently infected T-cell line, J-lat, and MDDCs. 466 
MDDCs resemble inflammatory DCs (82) and are involved in early pathogen-specific 467 
T-cell responses (98). Thus, they may act indirectly on latently infected cells upon 468 
activation. We used this model to determine if triggering the DC compartment in 469 
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concert with LRA had additive or synergistic effects over targeting latently infected 470 
cells alone.  471 
We first characterized the latency reversion features of various J-lat clones to 472 
established LRA (Fig. 1A). We found high LRA sensitivity disparity between the 473 
clones, that argues or clonal variegation leading to multiple refractory mechanisms to 474 
latency reversion (99). Moreover, maximum latency reversion was hardly achieved, 475 
These intrinsic features were also observed in primary cells (97). 476 
Then, we compared the potency of several known LRA on J-lat cells clone 9.2 alone 477 
or co-cultured with MDDCs (Fig. 1B). SAHA stood out for its ability to reverse HIV 478 
latency in J-Lat cells. In the co-culture model, however, this effect was partially lost. 479 
This observation is consistent with the immunosuppressive activity of HDAC 480 
inhibitors (100) and emphasizes the need to investigate LRA in more complex 481 
settings than only latently infected cell lines. Prostratin, a non-tumorigenic phorbol 482 
ester, showed some modest latency reversing activity in J-lat cells alone, as reported 483 
(51, 76). Notably, Prostratin reactivates latent HIV and restricts HIV replication via i) 484 
transient activation of several PKC isoforms (51), leading to NFκB and Cyclin T1 485 
availability (52), both being limiting factors for latency reversion, ii) cell-surface 486 
downregulation of CD4 and CXCR4 and DC-SIGN (43, 101) (Fig. 5C) and 487 
upregulation of the HIV restriction factor p21 (102, 103). Intriguingly, in the co-488 
cultures, Prostratin exhibited a substantially increased number and intensity of eGFP-489 
expressing cells, but the level of apoptosis was similar to J-lat cells alone (Fig. 1B). In 490 
contrast to SAHA, adding MDDCs reinforced substantially the LR effects of 491 
Prostratin, leading to MDDCs maturation and enhancing latency reversion.  492 
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We primarily tested the TLR agonists 2, 4 and 8 for their ability to stimulate the 493 
MDDCs. They had no effect when added to J-lat cells alone (Fig. 1B), consistent with 494 
the lack of TLR2, 4 and 8 mRNA expression even upon treatment (data not shown). 495 
In the co-culture system, TLR 4 and 8ag displayed potent activity in inducing HIV 496 
expression as judged by the eGFP expression in J-lat cells, but the TLR2ag had only 497 
a modest effect (Fig. 1B). TLR4 also triggers a prominent cytokine storm that would 498 
exclude its clinical application. In contrast, TLR7 and TLR7/8 agonists have been 499 
successfully and safely applied to patients with hepatitis B (104) and C (105) infection 500 
and thus are rationale candidates to test in concert with Prostratin. Notably, TLR8ag 501 
beneficially affected various steps leading to the generation of an efficient adaptive 502 
immune response (67, 74, 106). Importantly, Prostratin with the TLR8ag led to a 503 
significantly larger breadth and intensity of HIV latency reversion than Prostratin 504 
alone (Fig. 2D, F). These findings suggested a reinforcement of signaling events, 505 
which might target and reactivate various cell types, harboring diverse HIV 506 
transcription blocks in vivo.  507 
We choose another latently HIV infected T-cell line, namely, the J1.1 cell line (84) 508 
which was obtained by limiting dilution of HIV-1 LAV infected Jurkat E6 Cells, to 509 
corroborate the data observed with the J-lat cells. The J1.1 cell line, was very 510 
responsive to TNF and to the combination of Prostratin and TLR8ag, at the doses 511 
established in the J-lat clone 9.2 (Fig. 3). We observed similar effects in co-culture 512 
but they were less prominent compared to the J-lat clone 9.2. The differing reactivity 513 
to LRAs between these cell lines are consistent with the intrinsic sensitivity of most 514 
cell models to particular stimuli, as stated by Spina et al. (88). 515 
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TNF plays certainly a key role in the reversion of HIV latency in this setup. 516 
However, reversion of latency was still observed when excess of NAb against TNF 517 
was added (Fig. 4A, B). We found that cell-cell contact contributes to the reversion of 518 
latency in co-culture. Indeed, the transfer of supernatant from TLR8ag-stimulated 519 
MDDCs onto Prostratin-treated J-lat cells and the stimulation of J-lat cells with 520 
Prostratin and TNF, did not reach the level of reversion observed in the co-culture 521 
setup (Fig. 4D). Thus, soluble factors and cell-cell contact contributed to the overall 522 
effects observed.  523 
Further detailed characterization revealed that both compounds promoted 524 
phenotypical and functional maturation of MDDCs, the effects being more prominent 525 
in response to the TLR8ag than to Prostratin (Fig. 5). Secreted IL12p70 and CD83 526 
engagement might drive a Th1 immune response through i) NK activation, ii) naive 527 
CD8+ T-cell priming, iii) expansion and survival of antigen-specific CD8+ T memory 528 
cells (78, 107-110), and iv) restoration of exhausted CD8+ T cells (95, 96). 529 
Intriguingly, the maturation markers, CD80 and CD86 were most likely interacting 530 
with the inhibitory molecule CTLA-4, as their neutralization resulted in enhanced 531 
viability and eGFP expression. Indeed, CTLA-4 was induced on J-lat cells when 532 
adding MDDCs (Fig. 5E). Hence, blocking CTLA-4, together with Prostratin and 533 
TLR8ag treatment, might potentiate the shock and kill strategy (111). Similarly, ICOS 534 
was upregulated in co-culture upon Prostratin-mediated T-cell activation. However, 535 
increasing concentrations of ICOSL blocking antibodies did not reverse latency (data 536 
not shown), despite ICOSL expression by MDDCs (112). Of note, ICAM1, 537 
upregulated by TNF signaling on DCs, was recently associated with HIV reactivation 538 
in proliferating CD4+ T cells, in a similar system (113). Since Jurkat cells do not 539 
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multimerize LFA-1, crucial for its activation and interaction with ICAM1, we did not 540 
challenge this axis (114).  541 
Activation and latency reversion might proceed in parallel with cell death of the 542 
target, as well as in bystander cells. Therefore, promising LRAs should be evaluated 543 
for their potential side effects (Fig. 6). As expected, SAHA increased active Caspase-544 
3 up to sevenfold in J-lat cells, as reported (115, 116). Surprisingly, we observed a 545 
similar induction in MDDCs. In contrast, Prostratin induced a threefold increase of 546 
active Caspase-3 in J-lat cells and none in MDDCs. Importantly, adding the TLR8ag 547 
did not enhance the Prostratin-mediated apoptosis.  548 
In sum, the combination of stimuli chosen exhibited no detrimental effect on both 549 
cellular players, and the enhanced HIV transcription observed without increasing 550 
apoptosis might be optimal for providing an antigenic boost to CTLs.  551 
We next wondered if the combinatorial stimulation of J-lat cells and MDDCs would 552 
remove epigenetic blocks by looking at the acetylation status of lysine 9 on histone 553 
H3 (H3K9-ac). Upon cell stimulation, transcription factors recruit histone acetyl 554 
transferase (HAT) and nucleosome-remodeling complexes. They allow the binding of 555 
the transcriptional machinery through chromatin relaxation (117-120). Prostratin 556 
alone did not induce any H3K9 acetylation of the overall chromatin 24 h after 557 
stimulation while given together with TLR8ag, it resulted in a significant relaxation of 558 
the chromatin (Fig. 7). This result endorses the highly dynamic and tailored signaling-559 
induced chromatin remodeling paradigm. Thus, the combination of those compounds 560 
acted at multiple levels to reverse latency, through chromatin accessibility, NFκB and 561 
PTEFb induction in this model (121). On the other hand, SAHA treatment led to a 562 
global acetylation pattern, which was not correlated with reversion of latency, 563 
highlighting the heterogeneity of the latency mechanisms responsible for HIV latency.  564 
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Using a library of signaling inhibitors, we demonstrated here that blocking the 565 
non-receptor kinases SYK and MEK drastically reversed the effects on latently HIV-566 
infected cells, triggered by Prostratin and TLR8ag (Fig. 8A). Moreover, their signaling 567 
appeared crucial for all treatment in J-lat alone as in co-culture, indicating their 568 
activation by Prostratin (Fig. 8A, B). SYK is a key downstream molecule in various 569 
immuno-receptors signaling events, in pre-T cells, mature B cells (93, 122, 123) and 570 
in malignancies (124, 125), e.g., J-lat cells. MEK, belonging to the MAPK pathway, 571 
bridged the signaling events induced by Prostratin to latency reversion in J-lat cells 572 
and in co-culture.  573 
Various PKC isoforms translocate within the plasma membrane upon Prostratin 574 
stimulation, such as PKCβ (51). Indeed, we observed a significant, but not complete, 575 
contribution of PKCβ on latency reversion in J-lat cells. This highlighted the role of 576 
others PKC isoforms, such as novel PKC (e.g., δ,ε,η,θ), that participated in the 577 
overall response, through NFκB and PTEFb release (126). Of note, Prostratin-treated 578 
co-cultures showed stronger PKCβ implication than J-lat alone, arguing for multiple 579 
effects of Prostratin on both cell types (Fig. 8B). Addition of TLR8ag in the co-culture 580 
drastically reduced the implication of PKCβ, TBK1 and PDK1 in the ultimate 581 
outcome, pointing to the collaborative and redundant signaling events involved in this 582 
setup (Fig. 8C). Moreover, the downstream effector within the TLR pathway, TBK1 583 
(127), which participate in TNF production, demonstrated its relevance only in the co-584 
culture setup. We speculate that the TLR8-mediated MDDCs maturation and the 585 
subsequent interaction with J-lat cells reduced the involvement of PKCβ, TBK1 and 586 
PDK1 in the overall response, highlighting collaborative signaling events. 587 
Surprisingly, inhibition of phospholipase C reinforced HIV reactivation in all the setup 588 
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(Fig. 8A, B). This may reflect its interaction with SYK through LAT in T cells (128, 589 
129), a change in signaling homeostasis or an unspecific effect of the inhibitor. 590 
Finally, we confirmed the relevance of the approach investigated in primary cells 591 
from aviremic patients. First, we demonstrated that latency reversion in response to 592 
treatments was not just a stochastic event since the compounds were clearly superior 593 
to the mock control (Fig. 9A). Second, the LRAs’ potency was donor-dependent. Not 594 
even the positive control (anti-CD3/CD28/CD2) reversed latency uniformly (Fig. 9B). 595 
We also observed striking differences in the magnitude of latency reversion between 596 
compounds and donors. Actually, the extent of viral RNA production upon stimulation 597 
might be a crucial parameter for achieving the depletion of these cells (59). In 598 
particular, Prostratin+TLR8ag excelled in higher latency reversion in two donors than 599 
either Prostratin or TLR8ag alone. However, Prostratin+TLR8ag had no effect in two 600 
others; one of those was not reactivated even by the positive control. 601 
Several parameters might affect the sensitivity of primary latently infected cells to 602 
a given LRA, such as the number of latently infected cells, the CD4+ T-cell subset, 603 
the epigenetic status as well as the presence of inhibitory receptors (130). Since we 604 
had been working with plain PBMC and not enriched lymphocytes and monocytes, 605 
obtained with leukapheresis, we might indeed encounter the risk that in some 606 
specimens the number of latently infected cells were too low or even absent. The 607 
number of latently infected cells is very small in human with estimated 1 to 60 608 
provirus containing cells per million of CD4+ T cells (1, 97).  Thus, by using 0.5 609 
million of CD4+ T cells per condition, we estimated to have between 0.5 to 30 latently 610 
infected cells per condition. This could explain part of the variability observed, 611 
although HIV reactivation was detected in all the donors.  612 
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Another variable which may affect the outcome is the response of the ex vivo 613 
generated MDDCs to the TLR8ag and their interplay with autologous CD4+ T cells, 614 
as well as their survival in the co-cultures. Nevertheless, the data generated are very 615 
promising and should encourage future studies exploring combination therapies of 616 
immunomodulators and LRAs.   617 
In conclusion, we established a novel in vitro co-culture system for testing 618 
compounds that mediate latency reversion. We showed that the synergistic efficacy 619 
of Prostratin and TLR8ag in co-culture can remove various repressive latency 620 
mechanisms through concomitant signaling events and confirmed its applicability to 621 
primary cells.  622 
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 1068 
Legends: 1069 
Fig. 1. Latency reversing agents demonstrated differential potency on J-lat cell 1070 
clones or in co-culture of J-lat clone 9.2 with MDDC at a 10:1 ratio.  1071 
A) 105 J-lat clones were stimulated for 24 h with Prostratin, TNF with or without Aza-1072 
CdR in R-10 medium. The viability of treated J-lat clones (upper panel) was 1073 
determined by the FSC/SSC characteristics. Reversion of latency (lower panel) was 1074 
assessed by eGFP quantification, using flow cytometry, n=3, SD. B) J-lat cells clone 1075 
9.2 (upper panel) were treated for 24 h and analyzed for their viability and eGFP 1076 
expression. TNF treatment represented the positive control, n=4, SEM. Co-culture of 1077 
J-lat clone 9.2 with MDDCs, at a ratio 10:1 (lower panel), were similarly analyzed. 1078 
CD40L designated the positive control for the co-culture setup, n=6, SEM (two-tailed 1079 
paired t-test: **, 0.0072). The left Y axis depicted the viability and the right Y axis, the 1080 
latency reversion. TNF: 10 ng/ml; CD40L: 50 ng/ml; Prostratin: 0.5 μM; TSA: 0.1 μM; 1081 
SAHA: 10 μM; Aza-CdR: 0.5 μM; TLR2ag: 100 ng/ml; TLR4ag; 20 ng/ml; TLR8ag: 1 1082 
μM. 1083 
 1084 
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Fig. 2. Prostratin achieved superior HIV latency reversion in co-culture system, 1085 
and was enhanced by TLR8 agonist.  1086 
A) J-lat cells 9.2 were stimulated for 24 h with different concentrations of Prostratin. 1087 
The percentage of reactivated cells was quantified by LTR-driven eGFP expression 1088 
using flow cytometry and depicted on the right Y axis. Viability was illustrated on the 1089 
left Y axis, n=3. B) Correlation of the eGFP expression with J-lat cells viability (two-1090 
tailed Pierson correlation, n=3; SEM). C) Dose-dependent toxicity of Prostratin on 1091 
parental Jurkat T cell (two–tailed paired t-test: *, p=0.033 and 0.0119, for 0.1 μM and 1092 
0.5 μM, respectively, when compared to mock; **, p=0.0053; n=4; SEM). D) Co-1093 
culture of J-lat cells 9.2 and MDDCs at a ratio 10:1, stimulated with increasing 1094 
Prostratin concentrations with or without TLR8ag at 1 µM. Addition of TLR8ag 1095 
significantly increased the reactivation potency of Prostratin (two-tailed paired t-test; 1096 
**, p=0.0054; ***, p=0.0004; ****, p=<0.0001; n=6; SEM). E) Representative viability 1097 
of J-lat cells from Figure 2D. F) Representative mean fluorescence intensity (MFI) of 1098 
the eGFP expression by J-lat cells in the setup 2D; **, p=0.0098; ***, p=0.0007; ****, 1099 
p=<0.0001; n=6; SEM. EGFP, a surrogate marker for viral protein production, was 1100 
monitored using flow cytometry and viability based on the FSC/SSC characteristics.  1101 
 1102 
Fig. 3. Effects of Prostratin and/or TLR8ag on J1.1 cell lines alone or co-1103 
cultured with MDDCs at a 10:1 ratio. 1104 
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105 J1.1 cells (blue bars, n=3) alone or in co-culture with MDDCs (104) (red bars, 1105 
n=9) were stimulated for 24 h with Prostratin at 0.5 µM, TNF at 10 ng/ml and TLR8ag 1106 
at 1 µM with or without 1 µg/ml of Infliximab in R-10 medium. Reversion of latency 1107 
was assessed by intracellular p24 staining and quantified by flow cytometry, two-1108 
tailed paired t-test; *, p=0.0359; ****, p=<0.0001, SEM. 1109 
 1110 
Fig. 4. TNF and cell-cell interaction are involved in the enhanced reactivation 1111 
observed in co-culture.  1112 
A) Reactivation potency of Prostratin and TLR8ag in co-culture, using a 0.4 μm pore 1113 
transwell, 1 μg/ml Infliximab (TNF inhibitor), and their combination after 24 h of 1114 
culture, n=6, SEM. The percentage of eGFP expressed was normalized on the 1115 
reactivation of co-culture treated with 0.5 μM Prostratin and 1 μM TLR8ag per 1116 
experiment (two-tailed paired t-test on the normalized value; **: 0.0093 for the 1117 
transwell; **: 0.002 for the Infliximab; ***: 0.0003). B) Potency of 1 μg/ml of Infliximab 1118 
to inhibit TNF-mediated latency reversion, assessed on J-lat cells clone 9.2 with 1119 
increasing concentration of TNF (ng/ml), n=5, SEM. C) Upper panel: effect of 1 h 1120 
TLR8ag pre-treatment of MDDCs, followed by washing and co-culture with J-lat cells 1121 
9.2, in presence of Prostratin. Middle panel: Effect of 1 h Prostratin pre-stimulation of 1122 
MDDCs, followed by washing and co-culture with J-lat cells 9.2, in presence of 1123 
TLR8ag. Lower panel: 2 h TLR8ag pre-treatment of MDDCs, washed and cultured for 1124 
24 h in R-10 medium. Transfer of the supernatant onto J-lat cells and further cultured 1125 
for 24 h. Percentage of eGFP expressed was normalized on the reactivation of co-1126 
culture treated with 0.5 μM Prostratin and 1 μM TLR8ag, n=6, SEM. SN: supernatant, 1127 
(two-tailed paired t-test on the normalized value; *: 0.0342; **: 0.0021; ****: <0.0001). 1128 
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Normalized per experiment. D) Comparison of the latency reversion upon treatment, 1129 
between j-lat alone (n=10), supplemented with the SN from 1 h or 2 h TLR8ag-1130 
stimulated MDDCs (n=14) and in co-culture with MDDCs (n=14). The green dashed 1131 
line represented the latency reversion induced by the combination of Prostratin and 1132 
TNF on J-lat cells. TNF was used at 10 ng/ml. The upper purple dashed line 1133 
highlighted the enhanced latency reversion when co-culture was treated with 1134 
Prostratin and TLR8ag. Addition of Infliximab did not abolish this latency reversion as 1135 
depicted by the lower purple dashed line.  1136 
 1137 
Fig. 5. Prostratin and TLR8ag modulated the phenotypic and functional 1138 
characteristics of MDDC but CD80-86 and ICOSL had no role in the enhanced 1139 
reversion of latency in co-cultures exposed to TLR8ag and Prostratin.  1140 
A) Upper panels: Kinetics of 105 MDDCs stimulated with Prostratin, n=11, median. 1141 
Lower panels: Kinetics of MDDC treated with TLR8ag, n=8, median. The percentage 1142 
of CD80-, 83-, and 86-expressing cells was monitored up to 36 h by flow cytometry 1143 
and fluorescent antibodies. B) Fold-change of TNF, MIP1α and IL-12p70 1144 
concentrations in the supernatants of treated MDDCs with TLR8ag or Prostratin, n=6, 1145 
SEM. C) Fold-change of mean fluorescence intensity (MFI) of DC-SIGN and HLA-DR 1146 
to mock-treated MDDCs (two-tailed paired t-test; **, p=0.0021 and 0.0045, 1147 
respectively, n=9, SEM). D) Neutralizing antibodies (NAb) against CD80, 86 at 5 1148 
μg/ml each and/or Infliximab at 15 μg/ml were applied to co-cultures stimulated with 1149 
Prostratin and TLR8ag for 24 h. Viability, depicted on the left Y axis, and the 1150 
reactivation, right Y axis, from J-lat cells 9.2 were normalized on the co-culture 1151 
treated with Prostratin and TLR8ag (two-tailed paired t-test; *, p=0.0191; ***, 1152 
p=0.0001; n=9, SEM). Note that 95% of J-lat cells expressed CD28 (data not shown). 1153 
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E) Expression comparison of CTLA-4 (n=6) and ICOS (n=8) in J-lat cells alone (left 1154 
panel) or in co-cultures treated (right panel), n=6, (two-tailed paired t-test; *: 0.0131; 1155 
****, p<0.0001; n=8, SEM). Prostratin and TLR8ag concentrations were identical as in 1156 
Figure 4. 1157 
 1158 
Fig. 6. Prostratin triggered moderate apoptosis in J-lat cells and shows no 1159 
deleterious effect on MDDC.  1160 
The percentage of cells harboring an active Caspase-3 upon treatment is depicted. 1161 
A) J-lat cells, n=5. B) MDDCs, n=3. C) J-lat cells in co-culture, n=6. D) Correlation of 1162 
activated Caspase-3-positive J-lat cells, left Y axis, and corresponding eGFP 1163 
expression, right Y axis, upon treatment (two-tailed Pierson correlation; n=4). E) 1164 
Percentage of active Caspase-3 in J-lat cells, left Y axis, and corresponding eGFP 1165 
expression, right Y axis, in co-culture, n=9. Prostratin and TLR8ag concentrations 1166 
were identical as in Figure 3. SAHA was used at 1 μM and TNF at 10 ng/ml, SEM. 1167 
 1168 
Fig. 7. Prostratin and TLR8ag stimulated co-cultures increased moderately but 1169 
significantly the chromatin accessibility, enabling HIV transcription  1170 
Percentage of viable J-lat cells (blue line), eGFP expression (green line) and 1171 
acetylated lysine 9 of histone H3 (H3K9-ac, red line) of treated J-lat cells alone (left 1172 
panel, n=3) or in co-culture (right panel, n=9), SEM, (two-tailed paired t-test; **: 1173 
0.0025). The concentration of stimuli was identical to the Figure 6. 1174 
 1175 
Fig. 8. SYK, MEK, PKCβ mostly mediated the enhanced reversion of latency by 1176 
Prostratin and TLR8ag in co-cultures.  1177 
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Reduction of eGFP observed when J-lat alone (blue) or in co-culture (red) were pre-1178 
treated for 1 h with 500 nM of signaling pathways inhibitors. The dashed lines 1179 
represented the maximal reactivation obtained upon stimulation without the inhibitors. 1180 
A) Percentage of viability, left Y axis, and eGFP expression, right Y axis, of J-lat in 1181 
co-culture, pre-treated with kinase inhibitors, subsequently stimulated with Prostratin 1182 
and TLR8ag for 24 h (two-tailed paired t-test; ****, p<0.0001; ***, p=0.0002 for MEK 1183 
and 0.0003 for PKCβ; **, p=0.0044; *, p=0.0294; n=6, SEM). B)  Detailed inhibition of 1184 
latency reversion, upon Prostratin treatment, for every inhibitor used. C) Detailed 1185 
inhibition of latency reversion, upon Prostratin and TLR8ag stimulation, for every 1186 
inhibitor used (SYK, MEK, PKCβ, TBK1 and GSK3 from co-culture (red bars) already 1187 
presented in Fig. 8A). The effects of the inhibitors on J-lat 9.2 monoculture are 1188 
depicted with the black bars and on the co-culture with the red bars, n=3 for J-lat and 1189 
n=6 for the co-culture, SEM. 1190 
 1191 
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Fig. 9. Latency reversion in co-cultures with cells from aviremic HIV-infected 1192 
individuals in response to either Prostratin ± TLR8ag or CD3/CD28/CD2 1193 
stimulation 1194 
Autologous co-culture of CD4+ T cells (105) and MDDCs (104) from aviremic patients, 1195 
in quintuplicate, were stimulated with CD3/CD28/CD2 antibodies at 2.5 µl/ml, 1196 
Prostratin, TLR8ag or combined as previously, in R-10 medium supplemented with 5 1197 
µM of AZT and 50 nM of Efavirenz. Every 2 days, 50 µl of SN per well was collected 1198 
and pooled per donor and treatment for HIV viral RNA analysis. A) Average peak 1199 
values from the mock treated controls and the peak values from the treated co-1200 
cultures in copies/ml are shown (Mann-Whitney test, **: p=0.0052). B) Peak values of 1201 
HIV RNA from the individual donors in response to the various LRAs. The dashed 1202 
line represented the average mock values. 1203 
 1204 
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Table 1.  Patients characteristics 
 
Patients 
Number 
 
Age 
 
Gender 
 
MSM 
 
Plasma VL 
initital 1 
(copies/ml)
 
CD4 
initial 1 
(cells/µl)
 
Plasma VL 
final2 
(copies/ml)
 
CD4 
final2 
(cells/µl)
Duration 
HIV 
infection3 
(months) 
 
Time 
aviremia4 
(months) 
4 31 m No 32’000 265 <20 504 139 71 
5 33 f / 18’800 922 <20 1’140 133 60 
6 64 m Yes 125’500 117 <20 379 207 195 
7 47 m Yes 10’000’000 176 <20 584 44 34 
8 47 m Yes 15’900 137 <20 386 107 71 
9 53 m Yes 962’500 419 <20 1’112 240 122 
 
1 Plasma viral load and CD4+ T cells counts prior to cART initiation 
2 Plasma viral load and CD4+ T cells counts during the blood sampling 
3 Calculated as the time between the infection and the date of blood sampling  
4 Calculated as the time between the first time point with undetectable viral load and the date of blood sampling 
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